Predictive value of molecular dosimetry: individual versus group effects of oltipraz on aflatoxin-albumin adducts and risk of liver cancer
- PMID: 9264273
Predictive value of molecular dosimetry: individual versus group effects of oltipraz on aflatoxin-albumin adducts and risk of liver cancer
Abstract
Studies in animals and humans have established serum aflatoxin-albumin adducts as biomarkers of exposure to aflatoxin B1 (AFB1), a food-borne hepatocarcinogen. To assess the utility of measurements of aflatoxin-albumin adducts to predict risk of hepatocellular carcinoma (HCC), 123 male F344 rats were dosed with 20 microg of AFB1 daily for 5 weeks after randomization into three groups: no intervention; delayed-transient (500 ppm of oltipraz, weeks 2 and 3 relative to AFB1); or persistent (500 ppm oltipraz, weeks -1 to 5). Serial blood samples were collected from each animal at weekly intervals throughout aflatoxin B1 exposure and assayed for levels of aflatoxin-albumin by radioimmune assay. Area under the curve (AUC) values for aflatoxin-albumin adducts decreased 20 and 39% in the delayed-transient and persistent oltipraz intervention groups, respectively, as compared to no intervention. Similarly, the total incidence of HCC dropped from 83 to 60% (P = 0.03) and 48% (P < 0.01) in these groups. Tumor multiplicity was also reduced in the two oltipraz intervention groups, whereas time to HCC was increased. Mononuclear cell leukemia, a common neoplasm in F344 rats, was seen in 39% of the control animals, whereas the two oltipraz interventions reduced incidence to 18% (P = 0.05) and 13% (P = 0.01), respectively. Overall, a significant association was seen between biomarker AUC and risk of HCC (P = 0.01). However, when the predictive value of aflatoxin-albumin adducts was assessed within treatment groups, there was no association between AUC and risk of HCC (P = 0.56). Thus, aflatoxin-albumin adducts can be useful for monitoring population-based changes induced by interventions, such as in chemoprevention trials, but have limited utility in identifying individuals destined to develop HCC. As a consequence, the use of this biomarker in quantitative risk assessment should be pursued cautiously.
Similar articles
-
Transient intervention with oltipraz protects against aflatoxin-induced hepatic tumorigenesis.Cancer Res. 1993 Aug 1;53(15):3499-504. Cancer Res. 1993. PMID: 8339253
-
Protection against aflatoxin B1-induced hepatocarcinogenesis in F344 rats by 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz): predictive role for short-term molecular dosimetry.Cancer Res. 1991 Oct 15;51(20):5501-6. Cancer Res. 1991. PMID: 1680553
-
Intermittent dosing with oltipraz: relationship between chemoprevention of aflatoxin-induced tumorigenesis and induction of glutathione S-transferases.Cancer Res. 1995 Oct 1;55(19):4319-24. Cancer Res. 1995. PMID: 7671242
-
Biological relevance of adduct detection to the chemoprevention of cancer.Clin Cancer Res. 2004 Aug 1;10(15):4901-12. doi: 10.1158/1078-0432.CCR-04-0098. Clin Cancer Res. 2004. PMID: 15297390 Review.
-
Exposure biomarkers in chemoprevention studies of liver cancer.IARC Sci Publ. 2001;154:215-22. IARC Sci Publ. 2001. PMID: 11220661 Review.
Cited by
-
Chemopreventive effect of oltipraz on AFB(1)-induced hepatocarcinogenesis in tree shrew model.World J Gastroenterol. 2000 Oct;6(5):647-650. doi: 10.3748/wjg.v6.i5.647. World J Gastroenterol. 2000. PMID: 11819668 Free PMC article. No abstract available.
-
Aflatoxin: a 50-year odyssey of mechanistic and translational toxicology.Toxicol Sci. 2011 Mar;120 Suppl 1(Suppl 1):S28-48. doi: 10.1093/toxsci/kfq283. Epub 2010 Sep 29. Toxicol Sci. 2011. PMID: 20881231 Free PMC article. Review.
-
Retrospective and Prospective Look at Aflatoxin Research and Development from a Practical Standpoint.Int J Environ Res Public Health. 2019 Sep 27;16(19):3633. doi: 10.3390/ijerph16193633. Int J Environ Res Public Health. 2019. PMID: 31569703 Free PMC article.
-
Costs and efficacy of public health interventions to reduce aflatoxin-induced human disease.Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2010 Jul;27(7):998-1014. doi: 10.1080/19440041003677475. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2010. PMID: 20419532 Free PMC article. Review.
-
Resolution of eicosanoid/cytokine storm prevents carcinogen and inflammation-initiated hepatocellular cancer progression.Proc Natl Acad Sci U S A. 2020 Sep 1;117(35):21576-21587. doi: 10.1073/pnas.2007412117. Epub 2020 Aug 14. Proc Natl Acad Sci U S A. 2020. PMID: 32801214 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Research Materials